SCYL3

Across TCGA pan-cancer cohorts, SCYL3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SCYL3 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher SCYL3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SCYL3 expression acts as an unfavorable survival marker.

LGG, UCEC, and GBM are the cancer types where SCYL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	OS	Median	All	0.163	0.896	<.001	12	view →
UCEC	OS	Median	IV	0.259	0.770	<.001	12	view →
GBM	DFS	Median	All	0.064	0.257	.014	6	view →
LUSC	DFS	Median	All	0.064	0.791	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SCYL3–LGG (OS)

Open the LGG breakdown →